• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, May 15

Lupin Ltd has received final approval from the US regulatory authority to sell its generic version of cholesterol-drug Simvastatin. The US Food and Drug Administration approved Lupin's abbreviated new drug application (ANDA) for Simvastatin tablets in different strengths, the company told the Bombay Stock Exchange. Lupin's Simvastatin is the generic equivalent of Merck's Zocor tablets. Lupin now has 21 ANDAs approved by the USFDA, a note from the company said. Lupin shares closed at Rs 714, up 1.05 per cent on the BSE.

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Mock drill on chemical disaster management

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line